TNFRSF17 and neoplasm: The study by University of Pennsylvania (NCT02546167) revealed no correlation between baseline BCMA expression and the response rate;74 in contrast, the FCARH143 trial (NCT03338972) found differential BCMA expression on tumor cells of long-term responders versus relapse patients prior to the treatment.